Advocating the potential for a single dose of #SARSCoV2 vaccines @zeynep @michaelmina_lab https://www.nytimes.com/2020/12/18/opinion/coronavirus-vaccine-doses.html?action=click&module=Opinion&pgtype=Homepage …
The points for studying this are good but the public message to many for skipping the 2nd dose is troubling when we don't really know what protection that provides
-
-
I’m also skeptical of the suggestion of HCWs for RCT. The same factors that make them low risk (good infection control in most health care facilities) would make the trial take longer to deliver results. If the goal is fast results, this doesn’t seem like the right population.
-
Good points. That may argue for offering vax+vax/placebo to a population who’d get no vaccine at this point. Also following up systematically with people who sadly will miss anyway—as happens so much. Bonus, we could vaccinate them after finding them.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.